TEVA
Teva Pharma Industries Ltd ADR
NYSE: TEVA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$34.63
+0.20% today
Updated 2026-06-12
Market cap
$40.32B
P/E ratio
25.84
P/S ratio
2.32x
EPS (TTM)
$1.34
Dividend yield
—
52W range
$15 – $37
Volume
6.2M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B4.0
Quality
C7.0
Profitability
B+6.3
Valuation
B6/9
Piotroski F-Score
Moderate
0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$41.78
+20.65%
12-Month target
$29.25
-15.54%
Intrinsic (DCF)
—
Margin of safety
—
5 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z 0.28 — distress zone
- Negative free cash flow $-208.00M
- Debt/equity 2.05x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $14.93B | $15.85B | $16.54B | $17.26B | $17.35B | $17.1B |
| Net income | $-2.45B | $-559.00M | $-1.64B | $1.41B | $369.00M | — |
| EPS | — | — | — | — | $1.34 | $2.41 |
| Free cash flow | $1.04B | $842.00M | $749.00M | $1.15B | $-208.00M | — |
| Profit margin | -16.39% | -3.53% | -9.91% | 8.17% | 9.02% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-05 | ZAKS, TAL ZVI | Sale | 14,492 | — |
| 2026-06-05 | ZAKS, TAL ZVI | Buy | 14,492 | — |
| 2026-06-05 | SATCHI-FAINARO, RONIT | Sale | 14,492 | — |
Peer comparison
Smart narrative
Teva Pharma Industries Ltd ADR trades at $34.63. representing a P/E of 25.84x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 0.28, it sits in the distress. TTM revenue stands at $17.35B. with profit margins at 9.02%.
Frequently asked questions
What is Teva Pharma Industries Ltd ADR's stock price?
Teva Pharma Industries Ltd ADR (TEVA) trades at $34.63, on a P/E of 25.8x and a P/S of 2.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Teva Pharma Industries Ltd ADR overvalued?
Teva Pharma Industries Ltd ADR carries a Smart Value Score of 66/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Teva Pharma Industries Ltd ADR (TEVA)?
The 12-month analyst consensus target is $41.78, about 20.6% above the current $34.63. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of TEVA by 2030?
Our research-backed model puts the 2030 base case at $9.52, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Teva Pharma Industries Ltd ADR's revenue?
Teva Pharma Industries Ltd ADR's trailing twelve-month revenue is $17.35B, and our model projects it reaching about $23.10B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Teva Pharma Industries Ltd ADR's Altman Z-Score is 0.28, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.32x
ROE19.01%
Beta0.85
50D MA$33.41
200D MA$28.47
Shares out1.16B
Float1.08B
Short ratio—
Avg volume6.2M
Performance
1 week+0.00%
1 month+0.41%
3 months+20.51%
YTD+10.32%
1 year—
3 years—
5 years—